Content
Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug
Article By:
ChinaBio® Today
Read
Saturday, January 13, 2018 6:23 PM EDT
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US.
Week In Review: China Life Science Starts 2018 With $2 Billion Week
Article By:
ChinaBio® Today
Read
Saturday, January 6, 2018 5:40 PM EDT
Perennial Real Estate Holdings announced a $1.2 billion joint venture that will acquire and develop healthcare centers in China. It plans to concentrate on integrated mixed-use developments that are connected to China high speed railway stations.
3 Threats To Amazon You Must Own Today
Article By:
Jeff Yastine
Read
Tuesday, January 2, 2018 3:12 PM EDT
In a wide swath of industries — not just aerospace, but pharmaceuticals, chip manufacturing, packaging, chemicals, consumer goods, media, telecommunications and more — the game of M&A “musical chairs” is already underway.
Meridian Bancorp, Inc. Announces Completion Of Meetinghouse Bancorp, Inc. Acquisition
Article By:
NASDAQ GlobeNewswire
Read
Tuesday, January 2, 2018 11:46 AM EDT
Meridian Bancorp, Inc. announced today that, effective December 29, 2017, it has completed its acquisition of Meetinghouse Bancorp, Inc.
In this article: EBSB
15 Of The Best Mergers And Acquisitions Of 2017
Article By:
Zacks Investment Research
Read
Monday, January 1, 2018 9:30 PM EDT
Merger and acquisition activity in 2017 has been relatively quiet; deals were down 35% year-to-date through mid-November. The deals that were announced in 2017, though, were major,
Week In Review: 2017 Was Record Investment Year For China Life Science; Final Week Adds $669 Million
Article By:
ChinaBio® Today
Read
Saturday, December 30, 2017 4:42 PM EDT
Shanghai's SARI will pay $359 million to acquire a 90% interest in Group NMS, a Milan oncology biopharma. SARI is a biopharma investment firm affiliated with the Chinese Academy of Science research organization with the same name.
Sucampo Pharmaceuticals, Inc. Stock Climbs On Mallinckrodt PLC Buyout Deal
Article By:
ValueWalk
Read
Tuesday, December 26, 2017 11:15 AM EDT
Sucampo Pharmaceuticals, Inc. stock surged in early trading on Tuesday after the company finalized an agreement to sell itself to Mallinckrodt PLC for $2.1 billion. Excluding debt, the acquisition is valued at approximately $840 million.
The Market Before Christmas
Article By:
Vivian Lewis
Read
Sunday, December 24, 2017 12:12 PM EDT
The last trading day before Christmas-to-New Year week, when markets tend to be quiet, was mainly about closing deals before 2018 and Catalonia.
In this article: BHP, BNS, DTE, EC, SLB, VOD, AZSEY, MXCHF, RHHBY, AAPL, LBTYA, PDI, BITCOMP, FCAU, INVVY
Week In Review: Nearly $2 Billion Late-December Week For China Pharma Deals
Article By:
ChinaBio® Today
Read
Saturday, December 23, 2017 5:37 PM EDT
Nanjing Legend Biotech and Janssen Biotech will form a global partnership with Legend for its CAR-T candidate and Crown Bioscience, a CRO with facilities in China, Taiwan, US and Europe, will be acquired for $400 million by JSR Corporation of Japan.
Amazon Competition With Google, Home Depot Linked To Blink Buy, XPO Interest
Bitcoin Is Deflationary, Transparent, And Antifragile
Article By:
Foundation For Economic Education
Read
Thursday, December 21, 2017 2:15 AM EDT
Centralized, opaque, and debt-based, money is being disrupted by decentralized, open-source, competitive crypto-currencies.
In this article: BITCOMP